跳至主要内容
临床试验/CTRI/2023/12/060401
CTRI/2023/12/060401尚未招募4 期

To study the efficacy of Metformin as an anti-hyperglycemic agent in patients requiring Insulin therapy during the induction phase of Acute Lymphoblastic Leukemia treatment - NI

I0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
4 期
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Treatment-naïve, newly diagnosed adults (= 18 years of age) with ALL requiring Insulin therapy for hyperglycemia during first 14 days of Induction chemotherapy, coming to the Department of Hematology after the Ethical approval for the study is granted, and providing informed consent for inclusion in the study, will be included in the study.

排除标准

  • Known case or newly diagnosed Diabetic individuals or Already on Metformin therapy or with Contra-Indications to Metformin therapy

研究者

发起方
I

相似试验